<DOC>
	<DOC>NCT01075191</DOC>
	<brief_summary>Therapy with lopinavir/ritonavir (Kaletra) and one other protease inhibitor in Human Immunodeficiency Virus participants</brief_summary>
	<brief_title>Kaletra: Therapy With Double Protease Inhibitors</brief_title>
	<detailed_description>This study is intended to observe and collect data on the usage, dosing, tolerability, and effectiveness of lopinavir/ritonavir (Kaletra) when used as part of a Nucleoside Reverse Transcriptase Inhibitors-free double protease regimen. Enrollment in the study was independent of the decision to prescribe Kaletra.</detailed_description>
	<mesh_term>Immunologic Deficiency Syndromes</mesh_term>
	<mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Lopinavir</mesh_term>
	<mesh_term>HIV Protease Inhibitors</mesh_term>
	<mesh_term>Protease Inhibitors</mesh_term>
	<criteria>Participants with Human Immunodeficiency Virus infection Participants on lopinavir/ritonavir (Kaletra) and one other protease inhibitor Hypersensitivity against lopinavir, ritonavir or other ingredients Severe liver insufficiency No concomitant astemizole, terfenadine, oral midazolam, triazolam, cisapride, pimozide, amiodarone, ergotamine, dihydroergotamine, ergometrine, methylergometrine, vardenafil and St. John's wort</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2013</verification_date>
	<keyword>Viral load</keyword>
	<keyword>Resistance</keyword>
	<keyword>Double protease inhibitors</keyword>
	<keyword>Mutations</keyword>
	<keyword>Immune system</keyword>
	<keyword>Infection</keyword>
	<keyword>Nucleoside Reverse Transcriptase Inhibitors-free</keyword>
	<keyword>Human Immunodeficiency Virus</keyword>
</DOC>